The company is expecting that existing users from its technology access program are likely to purchase instruments when they become available later this year.
At the AGBT conference this week, the DNA synthesis discussed the new capture products and its overall business.
At AGBT, researchers described applications for rapid pathogen ID; evaluating DNA, RNA, and gene expression in one assay; and understanding tumor heterogeneity.
Validation results presented at the Association for Molecular Pathology meeting demonstrate that the test can be implemented clinically, replacing existing FISH and PCR assays.
Performed on the company's Safetube platform, GFC's Microscreen test uses DNA hybridization to detect biomarkers in methicillin-resistant Staphylococcus aureus.
Researchers used the approach to develop an assay to detect above-threshold triplet repeats in Huntington's disease, but also highlight a variety of other applications.
The British molecular genetics company recently announced a menu update for its SureSeq myPanel NGS Custom Cancer Panel offering.
The firm envisions applying its new PlexSet technology to the upper end of multiplex gene expression analysis as well as CRISPR validation applications.
The new study in NEJM describes six families that share a disorder caused by mutations in IKAROS, a protein that plays a role in immune cell development.
Fred Hutch researchers report that analysis of one metastatic prostate tumor sample captures most of the variation in an individual's various metastases.
The Atlantic reports that genetic counselors are coping with an influx of patients seeking advice on their direct-to-consumer genetic test results.
A small study finds differences between three genomic prostate cancer tests, Medscape reports.
In Nature this week: shared genetic architecture for asthma and allergic diseases, and more.
A survey of Canadians finds them to be divided on genetically modified food, the Ottawa Citizen reports.